Bicycle Therapeutics plc
BCYC
$7.16
$0.020.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 301.85% | -70.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 301.85% | -70.73% | |||
| Cost of Revenue | -20.30% | 24.02% | |||
| Gross Profit | 34.11% | -44.01% | |||
| SG&A Expenses | 11.79% | -19.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.67% | 11.65% | |||
| Operating Income | 24.31% | -23.36% | |||
| Income Before Tax | 25.62% | -28.04% | |||
| Income Tax Expenses | 188.74% | 78.75% | |||
| Earnings from Continuing Operations | 25.14% | -29.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.14% | -29.95% | |||
| EBIT | 24.31% | -23.36% | |||
| EBITDA | 24.86% | -23.82% | |||
| EPS Basic | 25.20% | -29.85% | |||
| Normalized Basic EPS | 25.68% | -27.93% | |||
| EPS Diluted | 25.20% | -29.85% | |||
| Normalized Diluted EPS | 25.68% | -27.93% | |||
| Average Basic Shares Outstanding | 0.07% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||